Document Detail

In vitro investigation into the potential of a mistletoe extract to alleviate adverse effects of cyclophosphamide.
MedLine Citation:
PMID:  20486623     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Mistletoe extracts have been shown to provide deoxyribonucleic acid (DNA)-stabilizing effects in human peripheral blood mononuclear cells (PBMC) in vitro. We investigated the effect of a mistletoe extract on PBMC with and without concomitant treatment with cyclophosphamide and compared mitochondrial activity and replication of normal PBMC with that of a T-cell leukemia cell line. DESIGN: The experiments were performed with PBMC of healthy blood donors and the T-cell leukemia Jurkat cell line. Cells were pre-incubated with mistletoe extract for 60 to 65 hours. 4-hydroperoxycyclophosphamide (4-hpc, precursor of 4-hydroxycyclophosphamide) was added for 2 hours, after which mitochondrial activity and replication were measured. All experiments were randomized and blinded. MAIN OUTCOME MEASURES: Cell mitochondrial activity and replication were assessed with spectrophotometric analysis of WST-1 reduction and BrdU incorporation. RESULTS: The application of 4-hpc consistently reduced mitochondrial activity and replication of PBMC and Jurkat cells. Mistletoe extract strongly enhanced PBMC mitochondrial activity and replication (with or without 4-hpc) and partially inhibited Jurkat cell replication (with 4-hpc only). Compared to mistletoe untreated cells, enhancement ofPBMC mitochondrial activity by mistletoe extract was independent of treatment with 4-hpc, but enhancement of PBMC replication by mistletoe extract was stronger when treated with 4-hpc. CONCLUSIONS: Mistletoe extract strongly stimulated healthy PBMC but not malignant Jurkat cells. In addition, mistletoe extract seemed to partially protect healthy PBMC-but not malignant Jurkat cells-from the cytostatic effect of 4-hpc. The results motivate further preclinical and clinical investigations of mistletoe extracts as an adjuvant medication in cancer therapy to alleviate side effects of conventional therapy.
Jessica Burkhart; Chantal W?lchli; Peter Heusser; Ulrike Weissenstein; Stephan Baumgartner; Anne-Catherine Andres
Related Documents :
16554833 - Genetically encoded fluorescent indicator for intracellular hydrogen peroxide.
20038443 - Dexamethasone attenuated bupivacaine-induced neuron injury in vitro through a threonine...
22617353 - Acetylcholinesterase inhibition, antioxidant activity and toxicity of peumus boldus wat...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Alternative therapies in health and medicine     Volume:  16     ISSN:  1078-6791     ISO Abbreviation:  Altern Ther Health Med     Publication Date:    2010 May-Jun
Date Detail:
Created Date:  2010-05-21     Completed Date:  2010-06-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502013     Medline TA:  Altern Ther Health Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  40-8     Citation Subset:  IM    
Institute of Complementary Medicine KIKOM, University of Bern, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Phytogenic / adverse effects,  pharmacology*
Cells, Cultured
Cyclophosphamide / adverse effects,  analogs & derivatives*,  pharmacology
Drug Therapy, Combination
Jurkat Cells / drug effects
Leukemia-Lymphoma, Adult T-Cell / drug therapy*
Leukocytes, Mononuclear / drug effects
Lymphocyte Activation / drug effects
Plant Extracts / pharmacology*
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Plant Extracts; 40277-05-2/4-hydroxycyclophosphamide; 50-18-0/Cyclophosphamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The effect of a contemplative self-healing program on quality of life in women with breast and gynec...
Next Document:  Evaluating tools that can be used to measure and manage breathlessness in chronic disease.